An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Astria Therapeutics (NASDAQ: ATXS) has announced it will present new preclinical data on its drug STAR-0215, aimed at treating hereditary angioedema (HAE), at the Fc Receptor and IgG Targeted Therapies Conference in Boston, Massachusetts, from April 26-28, 2022. Jou-Ku Chung, the Head of Clinical Pharmacology, will present on April 27 at 3:00 PM ET. STAR-0215 is designed as a long-acting monoclonal antibody with the potential for quarterly dosing, with plans to file an Investigational New Drug application mid-2022 and commence a Phase 1a trial thereafter.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will share new preclinical data for STAR-0215 in a presentation titled “Development of STAR-0215: An Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE” at the 2022 Fc Receptor and IgG Targeted Therapies Conference which takes place April 26-28 in Boston, Massachusetts.
The oral presentation will be presented in-person by Jou-Ku Chung, Head of Clinical Pharmacology and Translational Medicine at Astria Therapeutics, on Wednesday, April 27th at 3:00pm ET.
STAR-0125 is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long acting, effective attack prevention for HAE with dosing once every 3 months or longer. The company’s goal is to provide the most patient-friendly preventative treatment option for HAE. Astria expects to file an Investigational New Drug application for STAR-0215 mid-year and plans to initiate a Phase 1a trial shortly thereafter with initial results anticipated by year-end.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: expectations regarding the timing for the filing of an IND for STAR-0215; commencement of a Phase 1 clinical trial for STAR-0215 and the timing of initial results from such trial; the potential attributes and differentiated profile of STAR-0215 as a treatment for HAE; and the Company’s broader goal to meet the unmet needs of patients with rare and niche allergic and immunological diseases. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goals,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Company’s product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties: related to changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors, including the COVID-19 pandemic; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of pre-clinical studies may not be replicated in clinical studies, the Company’s ability to enroll patients in our clinical trials, and the risk that any of the Company’s clinical trials may not commence, continue or be completed on time, or at all; decisions made by, or feedback received from, the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and other review bodies with respect to STAR-0215 and any future product candidates; the Company’s ability to manufacture sufficient quantities of drug substance and drug product on a cost-effective and timely basis; the Company’s ability to obtain, maintain and enforce intellectual property rights for STAR-0215 and any other future product candidates; competition with respect to STAR-0215 in HAE or with respect to any other future product candidates; the anticipated position and attributes of STAR-0215 in HAE based on its pre-clinical profile, pharmacokinetic modeling and other data; the Company’s ability to manage its cash usage and the possibility of unexpected cash expenditures; the Company’s ability to obtain necessary financing to conduct its planned activities and to manage unplanned cash requirements; general economic and market conditions; as well as the risks and uncertainties set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. The Company may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on the Company’s forward-looking statements. Neither the Company, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
STAR-0215 is a monoclonal antibody aimed at preventing hereditary angioedema (HAE), with an expected quarterly dosing schedule.
When will Astria Therapeutics present new data on STAR-0215?
Astria Therapeutics will present new preclinical data on STAR-0215 at the Fc Receptor and IgG Targeted Therapies Conference from April 26-28, 2022.
Who is presenting the STAR-0215 data at the conference?
Jou-Ku Chung, Head of Clinical Pharmacology at Astria Therapeutics, will present the data on April 27, 2022.
What are the future plans for STAR-0215?
Astria Therapeutics plans to file an Investigational New Drug application for STAR-0215 mid-2022 and initiate a Phase 1a trial shortly thereafter.
What is the significance of STAR-0215 for patients with HAE?
STAR-0215 aims to provide a long-acting, effective attack prevention option for patients with hereditary angioedema, potentially improving treatment adherence.
